by Richard Daverman, PhD
January 21, 2014 -- Harbin Gloria Pharmaceuticals in-licensed China rights to a hypertension treatment developed by Korea’s Boryung Pharma, paying $5.4 million upfront. Fimasartan, known as Kanarb, is a novel non-peptide angiotensin II receptor antagonist (ARB), which acts as a vasodilator. It has been marketed in Korea since 2011. As part of the deal, Gloria promised a minimum of $75 million in China sales over the next ten years. More details....
Help employers find you! Check out all the jobs and post your resume.
